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Abstract 
Multiple sclerosis (MS) is the leading cause of neurological disability in young adults. 
Since the pathophysiology of MS is characterized by dissemination in space, as well as in 
time, the autonomic nervous system is inevitably damaged in the course of the disease in 
many patients and the proportion of affected patients increases with disease duration. 
Autonomic dysfunction (AD) in MS is explained by lesions in regions responsible for 
autonomic regulation such as nuclei in the periventricular region of fourth ventricle in the 
brainstem as well as medullar lesions. Reports about frequency of AD in MS patients 
vary notably between groups. Nevertheless its impact on quality of life is substantial but, 
unfortunately, often overlooked. The aim of this article is to present a concise review of 
various symptoms and signs of autonomic system dysfunction in MS. 
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Introduction 
 
Multiple sclerosis (MS) is the leading cause of neurological disability in young adults [1]. 
Since the pathophysiology of MS is characterized by dissemination in space, as well as in 
time, the autonomic nervous system is inevitably damaged in the course of the disease in 
many patients and the proportion of affected patients increases with disease duration [2]. 
Activity of the disease seems to affect the parasympathetic and sympathetic parts of the 
autonomic system in different patterns. While long-term disease activity leads to 
sympathetic dysfunction, parasympathetic dysfunction correlates with progression of 
clinical disability [3]. Autonomic dysfunction (AD) in MS is explained by presence of 
lesions in regions responsible for autonomic regulation, such as nuclei in the 
periventricular region of fourth ventricle in the brainstem as well as medullar lesions 
[4,5]. The total MRI brain MS lesion load is another pathologic substrate related to AD 
incidence as demonstrated by Saari et al [6]. On the other hand, AD has been related to 
MRI findings of cervical spinal cord atrophy rather than the presence of demyelinating 
lesions in that region, postulating that AD results not solely from demyelination but from 
axonal loss as well [7].  
Reports about frequency of AD in MS patients vary notably between groups. 
Nevertheless its impact on quality of life is substantial but, unfortunately, often 
overlooked. This is evident in scores used to assess neurological disability for clinical and 
research purposes such as the Kurtzke Expanded disability status scale (EDSS) where AD 
is underappreciated being represented with only bowel and bladder dysfunction.  
The aim of this article is to present a concise review of various symptoms and signs of 
autonomic system dysfunction in MS. 
 
Cardiovascular dysfunction    
Cardiovascular autonomic dysfunction is reported to be present in up to two-thirds of MS 
patients and is known to show deterioration during the course of the disease [8, 9]. 
Orthostatic intolerance occurs in up to 50% of MS patients [10]. It is characterized by 
symptoms such as dizziness, nausea and palpitations when assuming upright position or 
prolonged standing or sitting. Head up tilt table testing is a valuable diagnostic method 
used for assessment of impaired heart rate and blood pressure response to orthostatic 
challenge. Our group has observed a substantial number of MS patients with a variety of 
pathologic tilt table test results, such as orthostatic hypotension (OH) (Fig. 1) or postural 
orthostatic tachycardia syndrome (POTS) (Fig. 2) [11]. OH represents a significant and 
sustained decrease of blood pressure upon standing [12]. MS patients have a greater 
tendency to develop OH because of impaired sympathetic vasoconstrictory reflex 
responsible for maintaining adequate blood pressure after standing up from a supine 
position, lack of which causes subsequent pooling of blood into lower extremities [13]. 
POTS is characterized by sustained heart rate increase on orthostatic challenge without 
concomitant OH and is associated with symptoms of orthostatic intolerance [14]. POTS 
has been reported to occur frequently in MS and the connection of the two entities is 
explained by the presence of demyelinating brainstem and hemispheral lesions disrupting 
the physiological heart rate variability modulation [10,14]. Almost half of POTS patients 
complain of fatigue and the concomitant appearance of POTS and MS aggravates the dire 
sense of fatigue that MS patients often experience [15].  
There is a battery of other clinical tests commonly used to assess cardiac autonomic 
dysfunction such as deep breathing test and Valsalva maneuver. Sanya et al. used 
baroreflex stimulation to demonstrate that MS patients have impairment of both the vagal 
mediated heart rate variability, as well as sympathetic control of blood vessel tone [16]. 
An interesting hypothesis was postulated by Keselbrener et al. who found that age-related 
reduction in vagal activity occurred earlier in MS patients complaining of fatigue, 
assuming that this form of AD may well be the pathological cause of fatigue [17]. 
It is important to bear in mind that de novo appearance of cardiac symptoms in MS can 
actually be a sign of disease exacerbation. Acute central nervous system lesions can 
induce an increased release of catecholamines causing necrotic changes in cardiac 
myocytes [18]. This, in return, can disrupt the endocardial conduction system causing 
arrhythmias such as sinus bradycardia or paroxysmal atrial fibrillation [19,20]. There 
have even been reports of cardiogenic shock and pulmonary edema caused by MS relapse 
[21,22]. Although the catecholamine surge in acute brain lesions can lead to myocardial 
damage, such as demonstrated in Takotsubo syndrome, there is, as well, an association 
presence of demyelinating lesions in the brainstem and the disruption of central 
autonomic influence on cardiac and respiratory system [22,23]. MS therapy itself can 
contribute or cause cardiac pathology. Administration of high doses of corticosteroids to 
patients in relapse has been known to cause cardiac arrhythmias [24]. Mitoxantrone is 
occasionally used in patients that don’t respond favorably to immunomodulating therapy. 
It is a drug with potential cardiotoxic effect and should therefore be administered with 
caution [25]. Unfortunately, some of the newer immunomodulatory drugs have cardiac 
side effects as well. Fingolimod treatment initiation must be accompanied with cardiac 
monitoring since sinus bradycardia, as well as asistoly, has ocurrred following its 
administration [26,27]. 
The initial therapy of orthostatic intolerance is consisted of patient education, reassurance 
and administration of counter-pressure maneuvers [28]. The next step is pharmacological 
intervention with volume expanders, vasoconstrictors and adrenergic antagonists. Patients 
with cardiac arrhythmia or ventricular dysfunction should be treated in consultation with 
a cardiology specialist. A novel cardiac symptom in an MS patient without a history of 
heart disease should always raise suspicion of MS relapse and be treated accordingly.  
 
Bladder dysfunction 
Urinary symptoms can be present as either storage phase dysfunction leading to 
incontinence or voiding phase dysfunction resulting in retention and incomplete bladder 
emptying [29]. These symptoms occur in up to 97% of MS patients during the course of 
the disease [30]. Incontinence often leads to social embarrassment and can have a severe 
impact on quality of life. The economic burden it produces is not to be depreciated [31]. 
Bladder dysfunction in MS results mainly from demyelinating lesions affecting the spinal 
cord, interrupting neural connections from the pontine micturition center to the 
parasympathetic sacral micturition center [32]. This leads to sensitization of the so-called 
silent C fibers causing detrusor hyperactivity, the most common problem in MS patients 
[33]. This was corroborated by urodynamic studies, which found detrusor hyperreflexia 
to be the main abnormality present, followed by detrusor sphincter dyssinergia and the 
least number of MS patients showing detrusor hyporeflexia [34]. The most common 
urinary symptom reported from the same group of patients was urgency followed by 
frequency, urge incontinence, stress incontinence and dysuria [34]. 
Storage and voiding symptoms can be reduced in female patients by pelvic floor muscle 
training [35]. Suprapubic vibration and Crede manouever can be given a trial in patients 
with incomplete bladder emptying [36]. Pharmacological treatment of detrusor 
hyperreflexia is based on anticholinergics such as oxybutynin, which reduce detrusor 
activity. Intranasal desmopressin is applicated to decreases the number of voiding 
episodes and Botulinum toxin A injected intravesically has shown to be an efficient 
therapy for bladder overactivity [37,38,39]. Urinary retention and incomplete bladder 
emptying may lead to hydronephrosis and chronic renal failure. Therefore the residual 
urine volume should be always measured. If there is a raised post-micturition residual 
urinary volume, the most efficient, but incommodious therapy, is intermittent self-
catheterization [30]. α blockers can be used if the residual volume is not substantial but 
their efficacy is often limited [40]. In patients with neurogenic bladder not responding to 
conservative therapy, uretroileostomy may be performed in order to lower urinary tract 
pressure, although the perioperative morbidity necessitates careful risk to benefit 
assessment [41].  
Given the high incidence of bladder dysfunction in MS, urinary tract infections (UTI) 
pose a significant problem in this population. UTI, as any infection in MS patients, can 
cause transient neurologic worsening and can even trigger a relapse [42]. What’s even 
more concerning, UTI have been reported as the cause of up to 10% of deaths in MS 
patients [43]. Antibiotics should be administered when the infection’s symptomatic. As 
far as prevention of urinary infection is concerned, prophylactic administration of 
antibiotics doesn’t reduce clinical evident UTI but decreases the number of asymptomatic 
bacteriuria [44]. 
 
Sexual dysfunction 
More than 80% of MS patients report sexual dysfunction (SD) [45]. Patients should be 
reassured to talk freely about this intimate subject, as SD often happens to be overlooked 
or underestimated as a symptom and therefore denied the possibility of treatment. The 
pathogenesis of SD in MS might be the result of lesions disrupting the hypothalamic–
pituitary–adrenal and the hypothalamic–pituitary–gonadal axis [46]. There is, as well, an 
association between the presence of sphinteric disorders and some symptoms of SD  
[47,48]. Relapse of the disease itself doesn’t seem to add to the number of SD symptoms 
[49]. Most of the affected patients experience sexual hypoactivitiy [50]. Beside reduced 
libido, men are often disabled by erectile dysfunction and premature ejaculation whereas 
women experience reduced libido, decreased vaginal lubrication and difficulties in 
reaching orgasm [45]. This all contributes to MS patients having sexual intercourse less 
frequently compared to patients with other chronic diseases or healthy controls [47]. This 
is an important factor adding to relationship dissatisfaction felt by MS patients, as well as 
their partners [50]. Conceivably, there seems to be an association between cognition and 
impaired sexuality as patients with SD more often report symptoms such as memory and 
concentration problems [48]. 
 Sildenafil, an oral phosphodiesterase-5 inhibitor, is an effective agent for erectile 
dysfunction in men but has been of limited usefulness in women, showing only some 
improvement in the lubrication domain [51,52]. Another agent used for erectile 
dysfunction is apomorphine hydrochloride administered sublingually [53]. In women, 
hormonal therapy such as estrogen and methyltestosterone may be used to improve lack 
of libido and vaginal dryness [53]. Increased partner support has a positive effect on 
sexual satisfaction in MS patients stressing the importance of psychosocial interventions 
and couple support therapy [54].    
 
Bowel dysfunction 
Constipation is present in 43% of MS patients while fecal incontinence affects 51% of 
patients [55]. All together, 68% of MS population complains of bowel dysfunction 
symptoms [55]. Constipation is a result of not only disease exacerbation itself, but also of 
decreased ambulation of patients and concomitant medications that may alter bowel 
movement. As well, there is evidence of paradoxical puborectalis contraction in MS, 
corresponding to detrusor sphincter dyssinergia in patients with bladder symptoms [56]. 
Fecal incontinence results from impairment of external anal sphincter function [57]. 
Gastric emptying scintigraphy can be used to assess autonomic dysfunction of the 
gastrointestinal tract. MS patients tend to have slower gastric emptying rate, which is 
associated with symptoms such as sense of fullness, hiccups, vomiting and 
gastroesophageal reflux [58].  
Constipation treatment is based on laxatives and diet rich in fibers wit a high fluid intake 
[59]. Treatment of fecal incontinence is often unsatisfactory and relies on combining 
antimotility agents with rectal stimulants [32]. Transanal irrigation has mainly been used 
to treat symptoms in neurogenic bowel syndrome. A recent study has demonstrated its 
effectiveness in MS, with incontinence showing greater improvement than constipation 
[60]. Biofeedback behavioral therapy can lead to improvement of resistant bowel 
symptoms and alleviate depression associated with this type of symptoms [61]. 
 
Sleep disorders 
Many MS patients report sleeping-related difficulties. In a large study of more than 
thousand individuals with MS, prevalence of moderate or severe sleep problems was 
more than 50% [62]. The most common symptoms are difficulty initiating and 
maintaining sleep, frequent awakenings because of leg cramps and discomfort, snoring 
and nocturia [63]. Lack of sleep leads to increased fatigue, daytime somnolence and 
respiratory dysfunction episodes [64]. Involvement of hypothalamus on MRI is 
associated with increased fatigue [65]. There has been a report of hypersomnia and low 
orexin-1 level due to a demyelinating lesion in the hypothalamus [66]. However, studies 
in larger groups of patients with relapsing remitting MS have found cerebrospinal fluid 
levels of hypocretin-1 to be normal, and they didn’t observe a correlation with 
hypersomnolence [67]. Many of the drugs used in MS treatment, including 
immunomodulatory therapy, can cause dyssomnias [68]. Nocturnal polysomnography is 
the method of choice for analyzing the pattern of sleep and identifying the type of 
disorder. It is important to stress out that depression is strongly associated with sleep 
disorders and that their treatment should be considered concomitantly [69].  
Treatment of insomnias is pharmacologically based on short-term use of agents such as 
antihistaminics, benzodiazepines and sedating antidepressants with education on sleep 
hygiene, relaxation technics and behavioral therapy [70]. Other treatable entities that 
contribute to sleep problems such as pain, leg cramps and nocturia should be properly 
managed [62,69]. Treatment of sleep disorder results in improvement not only of 
patient’s sleepiness, but of feeling of fatigue, energy and well being [71].  
 
Sudomotor dysfunction 
Heat or increased ambient temperature is one of the most common factors known to 
worsen MS symptoms [72]. Sweating, the physiological response to heat is mediated by 
sympathetic activity. Decreased sudomotor response occurs significantly higher in MS 
patients than in healthy controls and is related to disease activity [73]. Thermoregulation 
is impaired in MS patients because of interruption in the central sudomotor pathways that 
originate in the preoptic region of the hypothalamus and descend to intermediolateral 
column of the spinal cord where they exit the central nervous system and travel to sweat 
glands via peripheral nerves [74]. Temperature increase can diminish the current needed 
for depolarization of axons [75]. Thus, hyperthermia can cause a neuro-blockade of 
partially demyelinated axons, which leads to neurologic deterioration known as Uhthoff’s 
phenomenon [76]. Since there have been reports that such deterioration can be long-
lasting, difficulties in thermoregulation may have a more serious influence on patients 
than previously suspected [77]. Head and neck cooling reduce body temperature and may 
provide alleviation of heat-induced symptoms in MS [78]. Avoidance of prolonged 
exposure to heat is recommended to all MS patients. 
 
Conclusion 
Virtually any part of the diverse autonomic system can be affected in MS, causing 
various symptoms and signs. Cardiovascular abnormalities compromise a group of 
potentially hazardous but often overlooked symptoms in MS patients. Their treatment 
does not differ from treatment in individuals without MS, but their abrupt appearance in 
patients with an established MS diagnosis must be viewed in the context of a possible 
disease relapse. The most frequent and often embarrassing manifestations of AD in MS 
are bladder and bowel symptoms. Their therapy is often unsatisfactory and can be 
strenuous to manage for the patient and their caregivers. Since UTI are known to 
contribute to mortality in MS, their management is of great importance, especially in 
patients with decreased mobility. Sexual dysfunction can be surrounded by an aura of 
taboo and is often omitted in the patient-doctor conversation. However, it must be 
actively sought for by the physician and appropriately treated as it greatly affects 
patients’ quality of life, as well as their social functioning. Sleep disorders cause 
significant aggravation to patients and may attribute to fatigue and deteriorate their 
perception of well-being. Sudomotor dysfunction is an under-investigated area in MS, 
showing potential as an auspicious part of AD research. 
An interdisciplinary approach is necessary for optimal management of autonomic 
symptoms in MS patients. As more and more studies are performed regarding AD in MS, 
the importance of autonomic evaluation of this group of patients continues to be 
emphasized. All physicians involved in the treatment and rehabilitation of MS patients 
should be familiar with this field of neurology.  
 
 
References 
1. Edmonds P, Hart S, Gao W, et al. Palliative care for people severely affected by 
multiple sclerosis: evaluation of a novel palliative care service. Mult Scler. 
2010;16:627–36. 
2. Gunal DI, Afsar N, Tanridag T, Aktan S. Autonomic Dysfunction in Multiple 
Sclerosis: Correlation with Disease-Related Parameters. Eur Neurol 2002;48:1–5. 
3. Flachenecker P, Reiners K, Krauser M, Wolf A, Toyka KV. Autonomic 
dysfunction in multiple sclerosis is related to disease activity and progression of 
disability. Mult Scler. 2001;7:327-34. 
4. Vita G, Fazio MC, Milone S, Blandino A, Salvi L, Messina C. Cardiovascular 
autonomic dysfunction in multiple sclerosis is likely related to brainstem lesions. 
J Neurol Sci. 1993;120:82–86. 
5. Stenager E, Asbeth NS. Sexual aspect of multiple sclerosis. Sem Neurol 
1992;12:120-24. 
6. Saari A, Tolonen U, Pääkkö E, et al. Cardiovascular autonomic dysfunction 
correlates with brain MRI lesion load in MS. Clin Neurophysiol. 2004;115:1473-
78. 
7. De Seze J, Stojkovic T, Gauvrit JY, et al. Autonomic dysfunction in multiple 
sclerosis: cervical spinal cord atrophy correlates. J Neurol. 2001;248:297–303. 
8. Acevedo AR, Nava C, Arriada N, Violante A, Corona T. Cardiovascular 
dysfunction in multiple sclerosis. Acta Neurol Scand. 2000;101:85-8. 
9. Nasseri K, TenVoorde BJ, Adèr HJ, Uitdehaag BM, Polman CH. Longitudinal 
follow-up of cardiovascular reflex tests in multiple sclerosis. J Neurol Sci. 
1998;155:50-4. 
10. Kanjwal K, Karabin B, Kanjwal Y, Grubb BP. Autonomic Dysfunction 
Presenting as Postural Orthostatic Tachycardia Syndrome in Patients with 
Multiple Sclerosis. Int J Med Sci. 2010;7:62-67. 
11. Adamec I, Bach I, Barušić AK, Mišmaš A, Habek M. Assessment of prevalence 
and pathological response to orthostatic provocation in patients with multiple 
sclerosis. J Neurol Sci. 2013;324:80-3. 
12. Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I. 
Consensus statement on the definition of orthostatic hypotension, neurally 
mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 
2011;21:69-72. 
13. Flachenecker P, Wolf A, Krauser M, Hartung HP, Reiners K. Cardiovascular 
autonomic dysfunction in multiple sclerosis: correlation with orthostatic 
intolerance. J Neurol. 1999;246:578-86. 
14. Adamec I, Lovrić M, Zaper D, et al. Postural orthostatic tachycardia syndrome 
associated with multiple sclerosis. Auton Neurosci. 2013;173:65-8. 
15. Carew S, Connor MO, Cooke J, et al. A review of postural orthostatic tachycardia 
syndrome. Europace. 2009;11:18-25. 
16. Sanya EO, Tutaj M, Brown CM, Goel N, Neundörfer B, Hilz MJ. Abnormal heart 
rate and blood pressure responses to baroreflex stimulation in multiple sclerosis 
patients. Clin Auton Res. 2005;15:213-8. 
17. Keselbrener L, Akselrod S, Ahiron A, Eldar M, Barak Y, Rotstein Z. Is fatigue in 
patients with multiple sclerosis related to autonomic dysfunction?  Clin Auton 
Res. 2000;10:169-75. 
18. Sörös P, Hachinski V. Cardiovascular and neurological causes of sudden death 
after ischaemic stroke. Lancet Neurol. 2012;11:179-88. 
19. Juric S, Mismas A, Mihic N,  Barac AM, Habek M. Newly onset sinus 
bradycardia in context of multiple sclerosis relapse. InternMed. 2012;51:1121-24. 
20. Chagnac Y, Martinovits G, Tadmor R, Goldhammer Y. Paroxysmal atrial 
fibrillation associated with an attack of multiple sclerosis. Postgrad Med J. 1986 
May;62:385-7. 
21. Uriel N, Kaluski E, Hendler A, Leitman M, Vered Z. Cardiogenic shock in a 
young female with multiple sclerosis. Resuscitation. 2006;70:153-7. 
22. Padley JR, Feneley MP, Hayward CS, Markus R. Neurocardiogenic pulmonary 
oedema: initial presentation of multiple sclerosis. Heart Lung Circ. 2012;21:853-
5. 
23. Bramow S, Faber-Rod JC, Jacobsen C, et al. Fatal neurogenic pulmonary edema 
in a patient with progressive multiple sclerosis. Mult Scler. 2008;14:711-5. 
24. Vasheghani-Farahani A, Sahraian MA, Darabi L, Aghsaie A, Minagar A. 
Incidence of various cardiac arrhythmias and conduction disturbances due to high 
dose intravenous methylprednisolone in patients with multiple sclerosis. J Neurol 
Sci. 201;309:75-8. 
25. Murray TJ. The cardiac effects of mitoxantrone: do the benefits in multiple 
sclerosis outweigh the risks? Expert Opin Drug Saf. 2006;5:265-74. 
26. Jeffery DR, Markowitz CE, Reder AT, Weinstock-Guttman B, Tobias K. 
Fingolimod for the treatment of relapsing multiple sclerosis. Expert Rev 
Neurother. 2011;11:165-83. 
27. Espinosa PS, Berger JR. Delayed fingolimod-associated asystole. Mult Scler. 
2011;17:1387-9. 
28. Benditt DG, Nguyen JT. Syncope: therapeutic approaches. J Am Coll Cardiol. 
2009;53:1741-51. 
29. Panicker JN, Fowler CJ. The bare essentials: uro-neurology. Pract Neurol. 
2010;10:178-85. 
30. Haensch CA, Jörg J . Autonomic dysfunction in multiple sclerosis. J Neurol. 
2006;253 Suppl 1:I3-9. 
31. Tapia CI, Khalaf K, Berenson K, Globe D, Chancellor M, Carr LK. Health-related 
quality of life and economic impact of urinary incontinence due to detrusor 
overactivity associated with a neurologic condition: a systematic review. Health 
Qual Life Outcomes. 2013;11:13. 
32. Thompson AJ, Toosy AT, Ciccarelli O. Pharmacological management of 
symptoms in multiple sclerosis: current approaches and future directions. Lancet 
Neurol. 2010;9:1182-99. 
33. Kalsi V, Fowler CJ. Therapy Insight: bladder dysfunction associated with 
multiple sclerosis. Nat Clin Pract Urol. 2005;2:492-501. 
34. Nakipoglu GF, Kaya AZ, Orhan G, et al. Urinary dysfunction in multiple 
sclerosis. J Clin Neurosci. 2009;16:1321-4. 
35. Lúcio AC, Perissinoto MC, Natalin RA, Prudente A, Damasceno BP, D'ancona 
CA. A comparative study of pelvic floor muscle training in women with multiple 
sclerosis: its impact on lower urinary tract symptoms and quality of life. Clinics 
(Sao Paulo). 2011;66:1563-8. 
36. Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of 
the bladder in multiple sclerosis. Postgrad Med J. 2009;85:552-9.  
37. Bosma R, Wynia K, Havlikova E, De Keyser J, Middel B. Efficacy of 
desmopressin in patients with multiple sclerosis suffering from bladder 
dysfunction: a meta-analysis. Acta Neurol Scand. 2005;112:1–5. 
38. Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of 
bladder symptoms of multiple sclerosis. Ann Neurol 2007; 62: 452–57. 
39. Habek M, Karni A, Balash Y, Gurevich T. The place of the botulinum toxin in the 
management of multiple sclerosis. Clin Neurol Neurosurg. 2010;112:592-6. 
40. O’Riordan JI, Doherty C, Javed M, Brophy D, Hutchinson M, Quinlan D. Do 
alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis? 
J Urol. 1995;153:1114–16. 
41. Legrand G, Rouprêt M, Comperat E, Even-Schneider A, Denys P, Chartier-
Kastler E. Functional outcomes after management of end-stage neurological 
bladder dysfunction with ileal conduit in a multiple sclerosis population: a 
monocentric experience. Urology. 2011;78:937-41. 
42. Metz LM, McGuinness SD, Harris C. Urinary tract infections may trigger relapse 
in multiple sclerosis. Axone. 1998;19:67-70. 
43. Redelings MD, McCoy L, Sorvillo F. Multiple sclerosis mortality and patterns of 
comorbidity in the United States from 1990 to 2001. Neuroepidemiology. 
2006;26:102-7. 
44. Morton SC, Shekelle PG, Adams JL, et al. Antimicrobial prophylaxis for urinary 
tract infection in persons with spinal cord dysfunction. Arch Phys Med Rehabil. 
2002;83:129–38. 
45. Tepavcevic DK, Kostic J, Basuroski ID, Stojsavljevic N, Pekmezovic T, Drulovic 
J. The impact of sexual dysfunction on the quality of life measured by MSQoL-54 
in patients with multiple sclerosis. Mult Scler. 2008;14:1131–36. 
46. Guo ZN, He SY, Zhang HL, Wu J, Yang Y. Multiple sclerosis and sexual 
dysfunction. Asian J Androl. 2012;14:530-5. 
47. Zorzon M, Zivadinov R, Bosco A, et al. Sexual dysfunction in multiple sclerosis: 
a case-control study. I. Frequency and comparison of groups. Mult Scler. 
1999;5:418-27. 
48. Demirkiran M, Sarica Y, Uguz S, Yerdelen D, Aslan K. Multiple sclerosis 
patients with and without sexual dysfunction: are there any differences? Mult 
Scler. 2006;12:209-14. 
49. Zorzon M, Zivadinov R, Monti Bragadin L, et al. Sexual dysfunction in multiple 
sclerosis: a 2-year follow-up study. J Neurol Sci. 2001;187:1-5. 
50. Schmidt EZ, Hofmann P, Niederwieser G, Kapfhammer HP, Bonelli RM. 
Sexuality in multiple sclerosis. J Neural Transm. 2005;112:1201-11. 
51. Fowler CJ, Miller JR, Sharief MK, Hussain IF, Stecher VJ, Sweeney M. A double 
blind, randomised study of sildenafi l citrate for erectile dysfunction in men with 
multiple sclerosis. J Neurol Neurosurg Psychiatry 2005;76:700–05. 
52. DasGupta R, Wiseman OJ, Kanabar G, Fowler CJ, Mikol DD. Efficacy of 
sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. J 
Urol 2004;171:1189–93. 
53. DasGupta R, Fowler CJ. Bladder, bowel and sexual dysfunction in multiple 
sclerosis: management strategies. Drugs. 2003;63:153-66. 
54. Blackmore DE, Hart SL, Albiani JJ, Mohr DC. Improvements in partner support 
predict sexual satisfaction among individuals with multiple sclerosis. Rehabil 
Psychol. 2011;56:117-22. 
55. Hinds JP, Eidelman BH, Wald A Prevalence of bowel dysfunction in multiple 
sclerosis. A population survey. Gastroenterology 1990;98:1538–42. 
56. Chia YW, Gill KP, Jameson JS, et al. Paradoxical puborectalis contraction is a 
feature of constipation in patients with multiple sclerosis. J Neurol Neurosurg 
Psychiatry. 1996;60:31-5. 
57. Waldron DJ, Horgan PG, Patel FR, Maguire R, Given HF. Multiple sclerosis: 
assessment of colonic and anorectal function in the presence of faecal 
incontinence. Int J Colorectal Dis 1993;8:220–224 
58. El-Maghraby TA, Shalaby NM, Al-Tawdy MH, Salem SS. Gastric motility 
dysfunction in patients with multiple sclerosis assessed by gastric emptying 
scintigraphy. Can J Gastroenterol 2005;9:141–145, Gupta YK. Gastroparesis with 
multiple sclerosis. JAMA. 1984;252:42. 
59. Wiesel PH, Norton C, Glickman S, Kamm MA. Pathophysiology and 
management of bowel dysfunction in multiple sclerosis. Eur J Gastroenterol 
Hepatol. 2001;13:441-8. 
60. Preziosi G, Gosling J, Raeburn A, Storrie J, Panicker J, Emmanuel A. Transanal 
irrigation for bowel symptoms in patients with multiple sclerosis. Dis Colon 
Rectum. 2012;55:1066-73. 
61. Preziosi G, Raptis DA, Storrie J, Raeburn A, Fowler CJ, Emmanuel A. Bowel 
biofeedback treatment in patients with multiple sclerosis and bowel symptoms. 
Dis Colon Rectum. 2011;54:1114-21. 
62. Bamer AM, Johnson KL, Amtmann D, Kraft GH. Prevalence of sleep problems in 
individuals with multiple sclerosis. Mult Scler. 2008;14:1127-30. 
63. Tachibana N, Howard RS, Hirsch NP, Miller DH, Moseley IF, Fish D. Sleep 
problems in multiple sclerosis. Eur Neurol. 1994;34:320-3. 
64. Fleming WE, Pollak CP. Sleep disorders in multiple sclerosis. Semin Neurol. 
2005;25:64-8. 
65. Zellini F, Niepel G, Tench CR, Constantinescu CS. Hypothalamic involvement 
assessed by T1 relaxation time in patients with relapsing-remitting multiple 
sclerosis. Mult Scler. 2009;15:1442-49. 
66. Oka Y, Kanbayashi T, Mezaki T, et al. Low CSF hypocretin-1/orexin-A 
associated with hypersomnia secondary to hypothalamic lesion in a case of 
multiple sclerosis. J Neurol. 2004;251:885-6. 
67. Constantinescu CS, Niepel G, Patterson M, et al. Orexin A (hypocretin-1) levels 
are not reduced while cocaine/amphetamine regulated transcript levels are 
increased in the cerebrospinal fluid of patients with multiple sclerosis: no 
correlation with fatigue and sleepiness. J Neurol Sci. 2011;307:127-31. 
68. Brass SD, Duquette P, Proulx-Therrien J, Auerbach S. Sleep disorders in patients 
with multiple sclerosis. Sleep Med Rev 2010;14:121–9. 
69. Bamer AM, Johnson KL, Amtmann DA, Kraft GH. Beyond fatigue: Assessing 
variables associated with sleep problems and use of sleep medications in multiple 
sclerosis. Clin Epidemiol. 2010;2:99-106. 
70. Caminero A, Bartolomé M. Sleep disturbances in multiple sclerosis. J Neurol Sci. 
2011;309:86-91. 
71. Chervin RD. Sleepiness, fatigue, tiredness, and lack of energy in obstructive sleep 
apnea. Chest. 2000;118:372–9. 
72. Gallup AC, Gallup GG Jr, Feo C. Yawning, sleep, and symptom relief in patients 
with multiple sclerosis. Sleep Med. 2010;11:329-30. 
73. Saari A, Tolonen U, Pääkkö E, et al. Sweating impairment in patients with 
multiple sclerosis. Acta Neurol Scand. 2009;120:358-63. 
74. Noronha MJ, Vas CJ, Aziz H. Autonomic dysfunction (sweating responses) in 
multiple sclerosis. J Neurol Neurosurg Psychiatry 1968;31:19–22. 
75. D.G. Baker. Multiple sclerosis and thermoregulatory dysfunction. J Appl Physiol. 
2002:92:1779–80. 
76. Guthrie TC, Nelson DA. Influence of temperature changes on multiple sclerosis: 
critical review of mechanisms and research potential. J Neurol Sci 1995;129:1–8. 
77. Berger JR, Sheremata WA. Persistent neurological deficit precipitated by hot bath 
test in multiple sclerosis. JAMA 1983;249:1751–3. 
78. Ku YT, Montgomery LD, Wenzel KC, Webbon BW, Burks JS. Physiologic and 
thermal responses of male and female patients with multiple sclerosis to head and 
neck cooling. Am J Phys Med Rehabil. 1999;78:447-56. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 
Figure 1. An example of head-up tilt test in MS patient with OH: Upper line shows 
continuous heart rate monitoring, lower line shows continuous blood pressure 
monitoring. Note the decrease of blood pressure after the tilt (vertical red line) > 20 
mmHg/10 mmHg, with a compensatory rise in blood pressure. 
 
 
 
 
Figure 2. An example of head-up tilt test in MS patient with POTS: Upper line shows 
continuous heart rate monitoring, lower line shows continuous blood pressure 
monitoring. Note the increase of heart rate after the tilt (vertical red line) >30 
beats/minute, without fall in blood pressure. 
 
 
